FDA Alert: Tarceva (erlotinib)

Medical News: FDA Clears New Indication for NSCLC Drug - in Product Alert, Prescriptions from MedPage Today

medpagetoday.com — “WASHINGTON -- Against the wishes of its advisory panel, the FDA has expanded its approval of erlotinib (Tarceva), a second-line drug used in treating non-small cell lung cancer (NSCLC), to include us” View full resource at medpagetoday.com

Most Recently Shared on April 20, 2010 at 7:27 pm By:

FightCancer Health News

FDA Clears New Indication for NSCLC Drug http://bit.ly/dc92kE

FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer | Business Wire

businesswire.com — “MELVILLE, N.Y.--(BUSINESS WIRE)--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Food and Drug Administration (FDA) approved the daily pill Tarceva® (erlotinib) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. “We are delighted that lung cancer patients and their physicians will have the option of beginning Ta” View full resource at businesswire.com

Most Recently Shared on April 19, 2010 at 3:36 pm By:

Naoto T. Ueno Oncologist, Physician, Doctor, and Internist

RT @cancer_drugs Business Week: FDA Approves Tarceva as Maintenance Therapy 4 Advanced Non-Small Cell Lung #cancer http://bit.ly/9ghaDc

Tarceva approved as maintenance therapy for advanced non-small cell lung cancer (NSCLC) - MPR

empr.com — “Genentech announced that the FDA has approved Tarceva (erlotinib tablets) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.” View full resource at empr.com

Most Recently Shared on April 19, 2010 at 3:17 pm By:

MPR Medical Publisher

MPR News: Tarceva approved as maintenance therapy for advanced non-small cell lung cancer (NSCLC): Genentech annou... http://bit.ly/aL6GEI

OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher

Tarceva approved as maintenance therapy for advanced non-small cell lung cancer (NSCLC) - ONA

oncologynurseadvisor.com — “Genentech announced that the FDA has approved Tarceva (erlotinib tablets) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.” View full resource at oncologynurseadvisor.com

Most Recently Shared on April 19, 2010 at 2:54 pm By:

Tarceva approved as maintenance therapy for advanced non-small cell lung cancer (NSCLC) http://goo.gl/fb/8XCZx

FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer

drugs.com — “Tarceva (erlotinib) is used to treat non-small cell lung cancer and pancreatic cancer. Includes Tarceva side effects, interactions and indications.” View full resource at drugs.com

Most Recently Shared on April 18, 2010 at 10:38 pm By:

Drugs.com Health Site

FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer - http://bit.ly/cVy4LL

News-Medical.Net Health News

Genentech's Tarceva receives FDA approval as maintenance therapy for advanced NSCLC

news-medical.net — “Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration approved the daily pill Tarceva® (erlotinib) as a maintenance treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.” View full resource at news-medical.net

Most Recently Shared on April 17, 2010 at 6:50 am By:

Stroke News: Genentech's Tarceva receives FDA approval as maintenance therapy for advanced NSCLC: Genentech, Inc... http://twurl.nl/kuh4rr

New warning, safety information issued for erlotinib | HemOncToday

hemonctoday.com — “FDA MedWatch informed health care professionals on Friday of new safety information added to the warnings and precautions portion of the pres” View full resource at hemonctoday.com

Most Recently Shared on January 22, 2010 at 6:10 am By:

HemOnc Today Oncology and Health News

New warning, safety information issued for erlotinib (Tarceva, OSI/Genentech) http://bit.ly/14nXc2

News-Medical.Net Health News

FDA Advisory Committee votes against the approval of Tarceva

news-medical.net — “OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against approval of the daily pill Tarceva® (erlotinib) for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has not progressed (grown or spread) following first-line treatment with platinum-based chemother” View full resource at news-medical.net

Most Recently Shared on December 17, 2009 at 5:01 pm By:

Lung Cancer News: FDA Advisory Committee votes against the approval of Tarceva: OSI Pharmaceuticals, Inc. and Genen... http://bit.ly/7LSOAw